Photodynamic Therapy in Ophthalmology

Authored by: Patrycja Nowak-Sliwinska , Andrea Weiss , Michel Sickenberg , Hubert van den Bergh

Handbook Ofphotomedicine

Print publication date:  October  2013
Online publication date:  October  2013

Print ISBN: 9781439884690
eBook ISBN: 9781439884706
Adobe ISBN:

10.1201/b15582-44

 Download Chapter

 

Abstract

Ocular photodynamic therapy (PDT) was introduced as effective treatment for neovascular forms of agerelated macular degeneration (AMD) and choroidal neovascularization (CNV) secondary to pathologic myopia in the late 1990s. It is worth mentioning that verteporfin PDT (v-PDT) was the first approved therapy for the treatment of subfoveal lesions and, at that time, was the only solution to avoid progressive vision loss and blind-ness. Verteporfin, or benzoporphyrin derivative monoacid ring A (BPD-MA), is a secondgeneration lipophilic/amphiphilic photosensitizer (PS) with an absorption peak centered at 689 nm. It is administrated as a liposomal formulation called Visudyne (Novartis Pharmaceuticals), which is a mixture of the two regio-isomers, each a racemic mixture of two enantiomers. Other PSs, such as hematoporphyrin derivative, were used in preclinical and clinical studies for ocular disorders with encouraging outcomes. These agents were later abandoned, however, due to their associated side effects and poor tissue penetration, and the search for new photosensitizers continued. Several other photosensitizers were tested in phase I/II clinical ophthalmological trials, including tin etiopurpurin (SnET2) and Lutetium texaphyrin (Lu-tex); however, they also failed to achieve market approval (Koh and Haimovici 2004).

 Cite
Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.